ライフサイエンスコーパス: viral vector

1 n-related adhesion protein (TRAP) by using a viral vector.

2 n in KO-SGCA mice by systemic injection of a viral vector.

3 tinal degeneration using an adeno-associated viral vector.

4 ssible, within the packaging capacity of the viral vector.

5 -PEG) self-assembling nanoparticle-based non-viral vectors.

6 siRNA to DCs is a challenging issue for non-viral vectors.

7 from lower delivery efficiencies compared to viral vectors.

8 the precision and versatility of drivers and viral vectors.

9 and foster engineering of improved oncolytic viral vectors.

10 hat distinguishes this from other known live viral vectors.

11 also modulate the efficiency of gene therapy viral vectors.

12 robust elevation of neurotrophins with these viral vectors.

13 and resolving the potential safety issues of viral vectors.

14 ed with transducing T cells with recombinant viral vectors.

15 icity and biosafety concerns of working with viral vectors.

16 s, for potential application as vaccines and viral vectors.

17 date for gene therapy using adeno-associated viral vectors.

18 or silencing using siRNA compared to that of viral vectors.

19 icity and biosafety concerns of working with viral vectors.

20 hepatocytes by recombinant adeno-associated viral vectors.

21 icity and biosafety concerns of working with viral vectors.

22 ral gene delivery vehicles to complement the viral vectors.

23 on of the method for use in adeno-associated viral vectors.

24 of genomic integration often associated with viral vectors.

25 or the production of both RNA- and DNA-based viral vectors.

26 dopaminergic neurons using adeno-associated viral vectors.

27 icted by the limited capacity of recombinant viral vectors.

28 re individually cloned into adeno-associated viral vectors.

29 rat striatum after stereotactic injection of viral vectors.

30 Tbx20, using a cardiotropic adeno-associated viral vector 9.

31 transcription factor CREB in the RSC with a viral vector, a manipulation known to enhance memory con

32 ed forelimb muscles with an adeno-associated viral vector (AAV) encoding human Neurotrophin-3 at a cl

33 ically approved serotype of adeno-associated viral vector (AAV1).

34 urons were transduced using adeno-associated viral vectors (AAV5) carrying either channelrhodopsin-2

35 e efficacy of an adeno-associated serotype 9 viral vector (AAV9) expressing miRYR2-U10 in correcting

36 administration of serotype 9 adenoassociated viral vectors (AAV9s) encoding sulfamidase corrects both

37 of long-acting recombinant adeno-associated viral vectors (AAVs) encoding anti-inflammatory and card

38 we used local injection of adeno-associated viral vectors (AAVs) encoding ligand-specific antagonist

39 lows us to optimize and monitor in real time viral vector administration into affected regions of the

40 g spinal glycinergic inhibitory neurons with viral vectors all have dramatic effects on pain and itch

41 6G>A mice using a synthetic adeno-associated viral vector, Anc80L65, shown to transduce 80-90% of sen

42 PIV5 is a promising live viral vector and has been used to develop vaccines.

43 We conclude that this viral vector and this delivery route hold great promise

44 vant and expressed it both in ChAd63 and MVA viral vectors and as a secreted protein-nanoparticle.

45 D overcomes the obstacle associated with non-viral vectors and can be considered to be a promising no

46 rly those that remove nonhuman agents (i.e., viral vectors and genetic sequences of bacterial origin)

47 LITEs can be packaged into viral vectors and genetically targeted to probe specific

48 re small, can be efficiently accommodated by viral vectors and have no detrimental effects on viral t

49 didate vaccines, despite employing disparate viral vectors and immunization strategies, consistently

50 Despite the biomedical utility of GALVs as viral vectors and in cancer gene therapy, full genome se

51 otype 5 (Ad5) is one of the most widely used viral vectors and is known to generate potent T cell res

52 otides are synthetic, free of the hazards of viral vectors and maintain small RNA information in a st

53 Recently engineered viral vectors and multi-subunit packaging RNAs have veri

54 as well as gene therapies that use improved viral vectors and newly developed genome editing technol

55 shown that inhaled gene therapy with various viral vectors and non-viral gene vectors is well tolerat

56 Both viral vectors and nonviral delivery systems can be devel

57 so achieved by combining R21 with TRAP-based viral vectors and protective efficacy was significantly

58 scuss employing NIS as a reporter gene using viral vectors and stem cells in imaging, diagnostic, and

59 The gene was packaged into adeno-associated viral vectors and then vitreally injected into rodent, n

60 ained comparable to that induced with single viral vectors and was less immunogenic than a heterologo

61 through which the innate immune response to viral vectors, and potentially other stimuli, may be con

62 ss this, we used a Cre-recombinase-dependent viral vector approach to express G(i/o)-coupled DREADDs

63 For AAV serotype 1 (AAV1), the first viral vector approved as a gene therapy treatment, and i

64 Viral vectors are a potent immunisation platform, benefi

65 Non-viral vectors are a preferred method of gene transfer du

66 type 9-encoding recombinant adeno-associated viral vectors are a rapid and versatile method to induce

67 combinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene therapy, vacc

68 Viral vectors are effective tools in gene therapy, but t

69 Viral vectors are efficient delivery agents but toxicity

70 We recently discovered that the viral vectors are more than passive vehicles for transcr

71 herapy using the biodegradable polymeric non-viral vector Arginine-grafted poly (cystaminebisacrylami

72 ene therapy via recombinant adeno-associated viral vectors as a viable treatment approach for many MD

73 These findings demonstrate a novel method of viral vector attenuation that could be used in both vacc

74 This study demonstrates the use of non-viral vector based oral delivery of GLP-1 gene through e

75 Viral vectors based on the adeno-associated virus (AAV)

76 The various viral vector-based clinical trials conducted in the past

77 also known to interfere with the efficacy of viral vector-based gene delivery.

78 Preclinical studies of viral vector-based HIV-1 vaccine candidates have previou

79 We provide preclinical evidence that viral-vector-based chemogenetic activation of, or restor

80 This requires that effective and stable viral vectors be developed for specific crops from endem

81 Using microinjection of adeno-associated viral vector bearing a transgene encoding FKBP1b into th

82 re one of the most potential alternatives to viral vectors because of their less immunogenicity, less

83 sically separated water masses, can serve as viral vectors, boosting host-virus contact rates and pot

84 otein immunizations synergize with DNA prime-viral vector boosts to enhance cellular and humoral immu

85 ssion of hamartin expression with TSC1 shRNA viral vectors both in vitro and in vivo increased the vu

86 s suggests that ectoparasites might serve as viral vectors, but evidence to date is scant.

87 to experimental cancer therapies that employ viral vectors, but little is known about the specific na

88 luenza virus H5 hemagglutinin expressed by a viral vector can elicit full protection against diverse

89 ction of an artificial microRNA carried in a viral vector can slow progression of hearing loss for up

90 Adeno-associated viral vectors can be used as a platform for delivering b

91 develop during the life span of these crops, viral vectors can be used for adding new genes as an alt

92 gene-based vaccines demonstrated that these viral vectors can mediate more potent protection against

93 In addition, selection of the viral vector capable of transfer of therapeutic gene int

94 apies more controllable, stimulus-responsive viral vectors capable of sensing and responding to speci

95 efficacy of a re-engineered adenoassociated viral vector carrying I-1c (BNP116.I-1c) in a preclinica

96 and rats injected with the adeno-associated viral vector carrying wild-type human alpha-synuclein.

97 s rats received intra-BLA microinjections of viral vectors carrying either halorhodopsin (eNpHR3.0-mC

98 Our probes facilitated injections of viral vectors carrying opsin genes while providing collo

99 After injections of viral vectors carrying the excitatory opsins ChR2 or C1V

100 Adeno-associated virus serotype 9 viral vectors carrying VEGF-B167 genes were infused intr

101 ng viral enhancers/promoters placed in foamy viral vectors caused extremely low immortalization of pr

102 udy demonstrates that following priming with viral vectors, CD4(+) T cell help is required to promote

103 xpressed individually in the non-replicating viral vectors ChAd63 and MVA, are capable of inducing an

104 PfUIS3 was expressed in the viral vectors chimpanzee adenovirus 63 (ChAd63) and modi

105 By using a Cre-dependent viral vector, ChR2 (tethered to mCherry) was expressed i

106 We injected adeno-associated viral vectors coding for Cre-dependent DREADDs or a cont

107 gle intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in l

108 al VMH microinjections of an adenoassociated viral vector containing either the SGLT1 short hairpin R

109 rformed IA injections of an adeno-associated viral vector containing the CLN2 gene (AAVrh.10CLN2), wh

110 A viral vector containing the gene for a synthetic inhibit

111 infection with recombinant adeno-associated viral vectors containing a wild-type allotopic human ND4

112 by infusion of recombinant adeno-associated viral vectors containing Cre recombinase (AAV-Cre).

113 f the Vglut2 gene, in which adeno-associated viral vectors containing genes encoding Cre recombinase

114 th continually emerging pathogens and pests, viral vectors could express genes to protect the plants

115 Treatment of human GSC-grafted mice with viral vector-delivered TLX shRNA or nanovector-delivered

116 Cas9 ribonucleoproteins and adeno-associated viral vector delivery of a homologous donor to achieve h

117 accumulation of Abeta following intracranial viral vector delivery or ex vivo manipulated intracrania

118 article, we describe our experience with AAV viral vector delivery system, that allows us to optimize

119 Vs for future clinical development using the viral-vectored delivery platform.

120 Stimulus-responsive viral vector design considerations as well as gaps in cu

121 We propose that viral vectors designed to deliver E6- and/or E7-specific

122 cultures transduced with an adeno-associated viral vector driving the GCaMP6f reporter behind a synap

123 which, when delivered by an adeno-associated viral vector, effectively inhibits HBV replication in HB

124 Capsid radioiodination of viral vectors enables non-invasive, whole body, in vivo

125 LR protein and could dampen adeno-associated viral vector encoded LDLR expression.

126 ation system to visualize oligomerization of viral vector-encoded alphaSYN fusion proteins.

127 loss through a cardiotropic adeno-associated viral vector encoding Carabin prevented transverse aorti

128 achment for the delivery of adeno-associated viral vector encoding Rab Escort Protein 1 is described

129 re transgenic mice received adeno-associated viral vectors encoding channelrhodopsin2 (ChR2), halorho

130 he adult mouse retina using adeno-associated viral vectors encoding Cre recombinase and short hairpin

131 Viral vectors encoding either enhanced green fluorescent

132 caques were transduced with adeno-associated viral vectors encoding hNTCP and subsequently infected w

133 ice were i.v. injected with adeno-associated viral vectors encoding murine IL-12 or luciferase under

134 epsy (TLE), gene therapy treatments based on viral vectors encoding NPY or galanin have been shown to

135 We stereotactically injected viral vectors encoding short hairpin RNA to knock down e

136 rogramming has been achieved with the use of viral vectors encoding transcription factors.

137 Viral vectors engineered to target PGE2 were capable of

138 mirrored the behavior of both viral and non-viral vectors, exhibiting liver tropism as well as enhan

139 of IL-10 in microglial cells, delivered via viral vectors expressed under CD11b promoter, significan

140 ced after treatment with an adeno-associated viral vector expressing a short hairpin RNA against Home

141 loxed Dicer1 alleles with an adenoassociated viral vector expressing Cre recombinase specifically in

142 lowing administration of an adeno-associated viral vector expressing Flag-micro-dystrophin (AAV-muDys

143 e delivery of a recombinant adeno-associated viral vector expressing follistatin (rAAV:Fst) to the hi

144 rainfluenza virus 5 (PIV5), a promising live viral vector expressing NA from avian (H5N1) or pandemic

145 rons of the ventral subiculum by injecting a viral vector expressing tetanus toxin light chain in mal

146 We inject an adeno-associated viral vector expressing the inhibitory DREADD, hM4Di, in

147 dy this, we administered an adeno-associated viral vector expressing VEGF-B or control vector to norm

148 ermore, sequential infection of ferrets with viral vectors expressing chimeric HA, aimed at boosting

149 al influenza virus vaccine strategy based on viral vectors expressing chimeric hemagglutinin construc

150 njected intracranially with adeno-associated viral vectors expressing human alpha-synuclein in the su

151 rt ongoing clinical trials to assess whether viral vectors expressing M.tb antigens that are shared b

152 eful platform in the clinical development of viral vectors expressing problematic transgenes.

153 ng and aged mouse HSCs labeled with barcoded viral vector, followed by assessing the skeletal distrib

154 12 (SFV-IL12) based on its promise as an RNA viral vector for cancer treatment.

155 and can be considered to be a promising non-viral vector for siRNA delivery to DCs, thus acceleratin

156 he HSV-1 VC2 vaccine strain may be used as a viral vector for the vaccination of horses as well as, p

157 neering approaches almost exclusively employ viral vectors for gene delivery to NSCs though safety an

158 nuously advancing development of recombinant viral vectors for gene therapy require that products are

159 d virus (AAV), one of the most commonly used viral vectors for gene therapy trials, and demonstrate t

160 ly relevant retroviruses due to their use as viral vectors for gene transfer and in cancer gene thera

161 on into defining the tendencies of different viral vectors for genomic integration.

162 The use of viral vectors for inner ear gene therapy is receiving in

163 certain insects, baculoviruses also serve as viral vectors for numerous biotechnological applications

164 entists who utilize cell-based, non-viral or viral vectors for suicide gene therapy of cancer make mo

165 d number of viruses have been developed into viral vectors for the purposes of gene expression or VIG

166 o enhance the capability of adeno-associated viral vectors for therapeutic gene delivery applicable t

167 Non-viral vector formulations comprise typically complexes o

168 mbinant proteins, DNA, replication-defective viral vectors, genetically disabled CMV, and inactivated

169 tudy suggests that scaffolds loaded with non-viral vectors harboring cmRNA encoding osteogenic protei

170 r injections of recombinant adeno-associated viral vectors harbouring a myosin transgene known to fac

171 proach for hMSC-based cell therapy using non-viral vectors has not been established.

172 To date, only viral vectors have achieved efficient gene silencing in

173 Recombinant viral vectors have been used as a vaccine platform to el

174 Viral vectors, however, are not devoid of safety issues

175 Initially, CSP is also delivered using these viral vectors; however, a reduction of anti-CSP antibodi

176 alone by using recombinant adeno-associated viral vector in the liver of three mouse models.

177 in processes occurring after arrival of the viral vector in the soma is responsible for the low tran

178 ors in Huh7 (HCC) cells and adeno-associated viral vectors in livers of mice.

179 iders a completely different set of uses for viral vectors in perennial fruit and nut crops, which ca

180 of the spatial and temporal distribution of viral vectors in vivo has generally required postmortem

181 human alpha-synuclein by local injection of viral-vectors in midbrain.

182 Viral vectors, in particular, are powerful gene delivery

183 e Cre-dependent expression of proteins using viral vectors--in particular, recombinant adeno-associat

184 and, once expressed in the mouse heart using viral vectors, induce cardiac regeneration after myocard

185 ty to abolish motor imbalance caused by aSyn viral vector injection with chronic 4 week PREP inhibiti

186 subunit deletion by injecting Cre-expressing viral vectors into the neocortex of GABAARgamma2(77I)lox

187 NCE Understanding the genotoxic potential of viral vectors is important in designing safe and efficac

188 elationships is vital if the efficacy of non-viral vectors is to match that of their viral counter-pa

189 These data show that two viral vectors label dopamine neurons with greater than 9

190 ht components to the motor cortex of mice by viral vectors labels a subset of excitatory and inhibito

191 ol DAT-cre mice, the VTA was targeted with a viral vector lacking the ChR2 gene (ChR2- group; n = 5).

192 functional properties with adeno-associated viral vector libraries and identify cardiotrophin-1 as a

193 These include challenges in viral vector-manufacturing capacity, where an estimated

194 ea that highly immunogenic vaccines, such as viral vectors, may be useful in the treatment of chronic

195 Viral vector mediated gene therapy has become commonplac

196 Local viral vector-mediated 5-HT2CR knockdown in the amygdala

197 Here we report that viral vector-mediated deletion of cacna1c in the adult p

198 leotides, short-interfering RNAs, as well as viral vector-mediated delivery of short hairpin RNAs and

199 croscopy detects similar ER enlargement, and viral vector-mediated delivery of YAP as well as chemica

200 Furthermore, viral vector-mediated expression of hNTCP on hepatocytes

201 Although viral vector-mediated gene therapy has been successfully

202 Adeno-associated viral vector-mediated transduction of CCBE1 into mouse s

203 Furthermore, viral vector-mediated transduction of green fluorescent

204 This study employed viral-vector-mediated cell-type-specific anterograde tra

205 In non-dependent rats, viral-vector-mediated knockdown of Prdm2 in the dmPFC re

206 es in the vmPFC (VGat-Cre(CeMA-vmPFC)) using viral-vector-mediated, cell-type-specific optogenetic te

207 Moreover, drMM cells transduced with viral vectors mediating Lhx1 knockdown were excluded fro

208 Using a viral-vectored model TB vaccine and a number of experime

209 enes to cells using semirandomly integrating viral vectors, newer genome editing technologies based o

210 Although viral vectors offer the greatest efficiency, they also r

211 Non-viral vectors often yield transgene expression levels lo

212 Pfs25-IMX313 expressed from viral vectors or as a protein-nanoparticle is significan

213 blocked tumor growth, both when delivered in viral vectors or as synthetic, clinically amenable, mole

214 injections of human alpha-synuclein carrying viral vectors, pathological accumulation of phosphorylat

215 Host immune response to viral vectors, persistence of nonintegrating vectors, an

216 naptic NMUR2 in the NAcSh using a retrograde viral vector potentiated cocaine sensitization.

217 ibodies were raised using a heterologous DNA-viral vector prime-boost regimen, resulting in a high pr

218 s for transgene induction involve the use of viral vectors prone to silencing and insertional mutagen

219 Although shortcomings in viral vector properties will render extension of such su

220 reakthroughs in recombinant adeno-associated viral vector (rAAV)-based gene therapy encouraged us to

221 herapy based on recombinant adeno-associated viral vectors (rAAV) shows promising therapeutic efficac

222 ed a recombinant adeno-associated serotype 2 viral vector (rAAV2), which drives P450scc expression an

223 -in particular, recombinant adeno-associated viral vectors (rAAVs)--have emerged as a widely used pla

224 nia virus Ankara (MVA), a safe and efficient viral vector, rapidly induces chemokine expression and r

225 describe methods for construction of rabies viral vectors, recovery of G-deleted rabies viruses from

226 one vaccine; and whether combining different viral vectors reduces anti-vector immunity to improve im

227 hippocampus of middle-aged male mice using a viral vector rejuvenates hippocampal function and improv

228 lecular details regarding plant responses to viral vectors remain elusive, which may complicate exper

229 ped a novel Pichinde virus (PICV)-based live viral vector, rP18tri, that packages three RNA segments

230 njection of rodent eyes with the recombinant viral vector scAAV2.dnRhoA.

231 cerebellum) of a recombinant adenoassociated viral vector serotype 2/5 (rAAV2/5) encoding human alpha

232 An adeno-associated viral vector serotype 8.LDLR-L318D\K809R\C818A vector th

233 in 2 patients who underwent adeno-associated viral vectors (serotype 2)-mediated NGF gene transfer.

234 pes) and self-complementary adeno-associated viral vectors, serotype-9 (scAAV-9) in spinal cord tissu

235 Heterologous prime-boost with the viral vectors simian adenovirus 63 (ChAd63)-modified vac

236 is the direct intravenous administration of viral vectors, so-called in vivo gene therapy.

237 Here, we used two complementary viral vector strategies to examine the effects of acute

238 In this study, we used a viral vector strategy to overexpress postsynaptic D2Rs i

239 posure vaccination with constructs involving viral vectors (such as vesicular stomatitis virus), and

240 ions of recombinant BDNF (into the ACC) or a viral vector synthesizing BDNF (into the ACC or S1) trig

241 ting the potential wide applications of this viral vector system for functional genomics studies in m

242 Using a Cre-inducible viral vector system to overexpress SIRT1 selectively in

243 eveloped such an approach utilizing a single viral vector system.

244 Using viral vectors taken up at axon terminals, we expressed c

245 Here, we focus on CHIKV vaccines that use viral-vector technologies.

246 Here, in young rhesus monkeys, we combined viral vector technology with assessments of anxiety and

247 Gene therapy using non-viral vectors that are safe and efficient at transfectin

248 en, we exploited recombinant adenoassociated viral vectors that enabled us to vary potential paramete

249 ge enzymes will be delivered as genes within viral vectors that enter hepatocytes.

250 cal costs of vaccination by mixing different viral vectors that share the same insert antigen in one

251 We show that salivary PYY augmentation, via viral vector therapy, rescues behavioral responsiveness

252 neurons (VgluT2-CB1 (-/-)) and Cre-dependent viral vector to express light-sensitive channelrhodopsin

253 ocampal microinjections of FKBP1b-expressing viral vector to male rats at either 13 months of age (lo

254 The possibility of integrating viral vectors to become a persistent part of the host ge

255 ons in energy balance, we used Cre-dependent viral vectors to both map their efferent projections and

256 use of gene transfer using adeno-associated viral vectors to deliver bNAbs.

257 Using viral vectors to deliver chemical tags into the mouse br

258 We used viral vectors to deliver peroxidase derivatives, which c

259 In this study, we used adeno-associated viral vectors to elevate circulating levels of the tumor

260 x-vivo transfer of therapeutic transgene via viral vectors to patient-derived autologous hematopoieti

261 ipulation of the form of Ag contained within viral vectors to produce the most effective and protecti

262 This allowed the viral vectors to raise robust anti-tumor adaptive immune

263 y sgRNAs transcribed from both synthetic and viral vectors to regulate BIA metabolism and biosynthesi

264 ns in energy homeostasis using cre-dependent viral vectors to selectively activate these neurons and

265 Using viral vectors to selectively delete mTOR in the ventral

266 t protein (EGFP)-expressing adeno-associated viral vectors to trace axonal projections from defined r

267 ial delivery of recombinant adeno-associated viral vectors to young adult SD mice can prevent many fe

268 e to insufficient transduction efficiency of viral vectors ("too little") and/or because the disease

269 used a combination of approaches, including viral vector transfections of insular cortex, arc fluore

270 livery of this construct by adeno-associated viral vectors upregulated MHC class I and MHC class II e

271 d driver and double reporter mouse lines and viral vectors using the Cre/Flp and Cre/Dre double recom

272 In the present study, we used viral vectors utilizing dynorphin or enkephalin promoter

273 of how anti-vector immunity maybe reduced in viral vector vaccination regimens.

274 Efficacy of Rv21 surpassed viral-vectored vaccination using ChAd63 and MVA.

275 ozoite antigens using protein-in-adjuvant or viral vectored vaccine delivery.

276 A key challenge in the field of therapeutic viral vector/vaccine manufacturing is maximizing product

277 rime-boost immunization with plasmid DNA and viral vector vaccines is an emerging approach to elicit

278 um, and delivered by either DNA vaccination, viral vector vaccines or as protein-in-adjuvant formulat

279 The successful introduction of viral vector vaccines to target M.tb and other pathogens

280 sing alternative to the use of DNA-based and viral vector vaccines, in part because of the potential

281 on with attenuated Plasmodium sporozoites or viral vectored vaccines can induce protective CD8(+) T c

282 Significantly, these novel viral-vectored vaccines induce strong immune responses c

283 in mice, for the delivery of novel bivalent viral-vectored vaccines.

284 and angiogenesis induced by adeno-associated viral vector-VEGF-C.

285 Ang-(1-9) was delivered by adeno-associated viral vector via single tail vein injection immediately

286 An adeno-associated viral vector was also used to reconstitute ORMDL3 expres

287 This MVA-H7-Sh2 viral vector was used to immunize ferrets and proved to

288 Using plasmid electroporation and AAV viral vectors, we delivered CRE-DOG to multiple GFP mous

289 Using viral vectors, we have found that progenitor populations

290 As an alternative to the use of viral vectors, we wanted to assess the efficacy of synth

291 Recombinant adeno-associated viral vectors were engineered to encode gain-of-function

292 n critical for the behavioral effects, hM4Di viral vectors were transduced and selectively expressed

293 mized, and, 14 weeks later, adeno-associated viral vectors were used to express ERalpha, ERbeta, or g

294 Our results show that combining a non-viral vector with UTMD technique is an effective strateg

295 Loading viral vectors with cGAMP therefore holds promise for vac

296 l copies on the chromosome or on plasmids or viral vectors with copy numbers in the hundreds.

297 comparison of HIV mutagenesis among various viral vectors with lower background error than tradition

298 we used convection-enhanced delivery of the viral vector, with online guidance from MRI.

299 T cells are refractory to transduction with viral vectors without extensive ex vivo stimulation, whi

300 lly requires the use of cationic carriers or viral vectors, yet issues related to cellular toxicity o